NEW TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER APPROVED
The EMA has approved a new drug for the benefit of patients with non-small cell lung cancer (NSCLC). It is amivantamab (Janssen), a new drug for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion activating mutations, following the failure of platinum-based therapy. […]
NEW TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER APPROVED Read More »
